Vident Investment Advisory LLC increased its position in shares of Aduro BioTech Inc (NASDAQ:ADRO) by 40.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 154,140 shares of the biotechnology company’s stock after purchasing an additional 44,325 shares during the quarter. Vident Investment Advisory LLC owned approximately 0.20% of Aduro BioTech worth $1,156,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Harvard Management Co. Inc. purchased a new stake in shares of Aduro BioTech during the third quarter worth approximately $69,418,000. State Street Corp lifted its stake in shares of Aduro BioTech by 8.3% in the 2nd quarter. State Street Corp now owns 684,699 shares of the biotechnology company’s stock valued at $7,808,000 after purchasing an additional 52,597 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Aduro BioTech by 12.4% in the 4th quarter. Geode Capital Management LLC now owns 355,653 shares of the biotechnology company’s stock valued at $2,667,000 after purchasing an additional 39,356 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Aduro BioTech by 3.8% in the 4th quarter. Millennium Management LLC now owns 298,441 shares of the biotechnology company’s stock valued at $2,238,000 after purchasing an additional 10,991 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Aduro BioTech by 52.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 294,007 shares of the biotechnology company’s stock valued at $2,205,000 after purchasing an additional 100,979 shares during the last quarter. Hedge funds and other institutional investors own 44.94% of the company’s stock.
In other Aduro BioTech news, insider Stephen T. Isaacs sold 72,051 shares of Aduro BioTech stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $8.48, for a total value of $610,992.48. Following the transaction, the insider now directly owns 231,380 shares in the company, valued at approximately $1,962,102.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Elsas Andrea Van sold 6,874 shares of Aduro BioTech stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $6.48, for a total value of $44,543.52. Following the completion of the transaction, the insider now owns 216,669 shares in the company, valued at $1,404,015.12. The disclosure for this sale can be found here. Insiders have sold a total of 106,874 shares of company stock worth $870,931 in the last 90 days. 6.60% of the stock is currently owned by company insiders.
Several equities analysts have recently commented on the company. ValuEngine raised Aduro BioTech from a “strong sell” rating to a “sell” rating in a research note on Wednesday, March 14th. Canaccord Genuity reaffirmed a “buy” rating on shares of Aduro BioTech in a research note on Friday, March 2nd. Bank of America decreased their target price on Aduro BioTech from $9.00 to $8.00 and set an “underperform” rating on the stock in a research note on Friday, March 2nd. Zacks Investment Research lowered Aduro BioTech from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Finally, BidaskClub raised Aduro BioTech from a “sell” rating to a “hold” rating in a research note on Wednesday, March 7th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $14.50.
Shares of Aduro BioTech stock opened at $8.95 on Thursday. Aduro BioTech Inc has a 12-month low of $5.82 and a 12-month high of $14.05.
TRADEMARK VIOLATION NOTICE: “Aduro BioTech Inc (ADRO) Shares Bought by Vident Investment Advisory LLC” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2018/03/22/aduro-biotech-inc-adro-shares-bought-by-vident-investment-advisory-llc.html.
Aduro BioTech Profile
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.